Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study

Daniel Toman, Petr Vavra, Petr Jelinek, Petr Ostruszka, Peter Ihnat, Ales Foltys, Anton Pelikan, Jan Roman, Daniel Toman, Petr Vavra, Petr Jelinek, Petr Ostruszka, Peter Ihnat, Ales Foltys, Anton Pelikan, Jan Roman

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD), often associated with obesity and metabolic syndrome, manifests itself as steatosis, hepatic fibrosis, cirrhosis, or even end-stage liver disease. NAFLD causes inflammation, insulin resistance and cardiovascular complications. The current study aimed to evaluate the beneficial effects of bariatric surgery on biochemical parameters of hepatic functions in obese patients by comparing them before and one-year after the surgery.

Methods: A total of 72 morbidly obese patients underwent bariatric surgery between 2016 and 2018. The incidence of diabetes mellitus in this group was 29%, median body weight was 124.5 kg (109.0-140.0) and mean body mass index (BMI) was 44.38 ± 6.770 kg/m2. The used surgical procedures included gastric bypass, sleeve gastrectomy, laparoscopic gastric plication, and single anastomosis duodeno-ileal bypass-sleeve gastrectomy. Biochemical parameters including ALT/AST ratio (AAR), NAFLD fibrosis score (NFS), hepatic fibrosis index (FIB-4) and Fatty Liver Index (FLI) were evaluated in all patients at the time of surgery and one year after the intervention.

Results: Significant improvement after the intervention was observed in 64 patients. A significant reduction in body weight (P<0.0001), waist circumference (P<0.0001), and body mass index (P<0.0001) were observed. NAFLD liver fibrosis index changed significantly (P<0.0001), suggesting a trend of improvement from advanced fibrosis towards stages 0-2. The FIB-4 fibrosis index indicated significant improvement (P=0.0136). Besides, a significant decline in hepatic steatosis (P<0.0001) was observed after bariatric surgery as compared to the pre-surgery fatty liver conditions.

Conclusion: Among the strategies to overcome NAFLD-associated impediments, bariatric surgery can be considered effective in reducing obesity and metabolic co-morbidities.

Trial registration: ClinicalTrials.gov (NCT04569396).

Keywords: NAFLD; bariatric surgery; liver fibrosis; obesity.

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008;24(3):320-7.
    1. Dixon JB, Bhathal PS, O'brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1):91-100.
    1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16):1221-31.
    1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30
    1. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PloSOne 2010;5:e13577.
    1. Day CP. From fat to inflammation. Gastroenterology 2006;130(1):207-10.
    1. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140(2):197-208.
    1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58(3):593-608.
    1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49(1):306-17.
    1. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36(6):1349-54.
    1. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008;32(9):1431-37.
    1. Organization WH. Obesity and overweight (Fact sheet N 311) http://www. who. int/mediacentre/factsheets/fs311/en. In.: Accessed; 2015.
    1. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56(12):1760-69.
    1. Wong VW-S, Wong GL-H, Choi PC-L, Chan AW-H, Li MK-P, Chan H-Y, Chim AM-L, Yu J, Sung JJ-Y, Chan HL-Y. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59(7):969-74.
    1. Puterbaugh J. The emperor's tailors: the failure of the medical weight loss paradigm and its causal role in the obesity of America: I can easier teach twenty what were good to be done than to be one of the twenty to follow mine own teaching. The brain may devise laws for the blood, but a hot temper leaps o'er a colddecree. Portia, Merchant of Venice. Diabetes, Obe Metab 2009;11(6):557-70.
    1. Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40(4):820-6.
    1. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, Uribe M, Méndez-Sánchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 2016;65(8):1196-207.
    1. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006;130(6):1848-52.
    1. Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol 2006;40:S44-S50.
    1. Livingston EH. The incidence of bariatric surgery has plateaued in the US. Am J Surg 2010;200(3):378-85.
    1. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. Jama 2004;292(14):1724-37.
    1. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, LaMonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357(8):753-61.
    1. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011;253(3):484-7.
    1. Reha JL, Lee S, Hofmann LJ. Prevalence and predictors of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery: a Department of Defense experience. Am Surg 2014;80(6):595-9.
    1. Weiner R. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010;28(1):274-9.
    1. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, Wakabayashi G. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol 2014;5:164.
    1. Panel NIoHCD. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991,115:956-61.
    1. Sallie R, Michael Tredger J, Williams R. Drugs and the liver part 1: Testing liver function. Biopharm Drug Dispos 1991;12(4):251-9.
    1. Cazzo E, Jimenez LS, Pareja JC, Chaim EA. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg 2015;25(6):982-5.
    1. Obese H. Body Mass Index (BMI). Obes Res 1998;6(2):51S-209S.
    1. Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine 2015;94(40):e1682. doi: 10.1097/MD.0000000000001682
    1. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE. Body mass index and the risk of stroke in men. Arch Intern Med 2002;162(22):2557-62.
    1. Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev 2013;34(3):117.
    1. Rief P, Pichler M, Raggam R, Hafner F, Gerger A, Eller P, Brodmann M, Gary T. The AST/ALT (De-Ritis) ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Medicine 2016;95(24):e3843.
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005-23.
    1. Castera L, Chan H, Arrese M. European Associatio n for Study of Liver; Asociacion Latinoamericana para el Estudio de l Higado. EASL-ALEH clinical practice guidelines: non-invasive test s for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237-64.
    1. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
    1. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617-49.
    1. LIVER CCOA. Chronic liver Disease. Essentials of Family Medicine 2008;341.
    1. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29(1):62-7.
    1. Cheah MC, McCullough AJ, Goh GB-B. Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. J Clin Transl Hepatol 2017;5(3):261.
    1. Hussain Shaikh F, Zeb S, Aziz Siddiqui K, Aamir Ghori M, Sadik Memon M, Zaki M. Fib-4 index: diagnostic validity for predicting hepatic fibrosis in south east asian patients of chronic hepatitis c virus (HCV) genotype 3 infection. Prof Med J 2017;24(10):1501-9.
    1. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, Network NCR. Use of the FIB4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104.
    1. Castiglione A, Bedogni G, Miglioli L, Crocè L, Masutti E, Passalacqua M, Bellentani S. 676 The fatty liver index: A simple and accurate predictor of hepatic steatosis. J Hepatol 2006,44:S249-S50.
    1. Fried M, Yumuk V, Oppert J, Scopinaro N, Torres A, Weiner R, Yashkov Y, Frühbeck G. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg 2014;24(1):42-55.
    1. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB. AACE/TOS/ASMBS Guidelines. Obesity 2009;17(S1):S3-72.
    1. Thorell A, MacCormick A, Awad S, Reynolds N, Roulin D, Demartines N, Vignaud M, Alvarez A, Singh P, Lobo D. Guidelines for perioperative care in bariatric surgery: enhanced recovery after surgery (ERAS) society recommendations. World J Surg 2016; 40(9):2065-83.
    1. Sánchez-Pernaute A, Herrera MAR, Pérez-Aguirre ME, Talavera P, Cabrerizo L, Matía P, Díez-Valladares L, Barabash A, Martín-Antona E, García-Botella A. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). One to three-year follow-up. Obes Surg 2010;20(12):1720-26.
    1. Brethauer SA, Harris JL, Kroh M, Schauer PR. Laparoscopic gastric plication for treatment of severe obesity. Surg Obes Relat Dis 2011;7(1):15-22.
    1. Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N. Sleeve gastrectomy-a restrictive procedure? Obes Surg 2007;17(1):57.
    1. Fobi MA, Lee H, Holness R, Cabinda D. Gastric bypass operation for obesity. World J Surg 1998;22(9):925-35.
    1. Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. FP Essent. 2015;435:24-9.
    1. Hafeez S, Ahmed MH. Bariatric Surgery as Potential Treatment for Nonalcoholic Fatty Liver Disease: A Future Treatment by Choice or by Chance? J Obes 2013;2013:839275. doi:10.1155/2013/839275
    1. Kral JG, Thung SN, Biron S, Hould F-S, Lebel S, Marceau S, Simard S, Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135(1):48-58. doi:10.1016/j.surg.2003.10.003
    1. Nostedt JJ, Switzer NJ, Gill RS, Dang J, Birch DW, de Gara C, Bailey RJ, Karmali S. The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease. Can J Gastroenterol Hepatol 2016;2016:2059245. doi:10.1155/2016/2059245
    1. Panagiotou OA, Markozannes G, Kowalski R, Gazula A, Di M, Bond DS, Ryder BA, Adam GP, Trikalinos TA. AHRQ Technology Assessments. Short- and Long-Term Outcomes after Bariatric Surgery in the Medicare Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018. Jan 7. Available from:
    1. Sharaiha RZ, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, Tyberg A, Kumar R, Igel L, Verna EC, Schwartz R, Frissora C, Shukla A, Aronne LJ, Kahaleh M. Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. Clin Gastroenterol Hepatol 2017;15(4):504-10. doi:10.1016/j.cgh.2016.12.012
    1. Doležalova-Kormanova K, Buchwald JN, Skochova D, Pichlerova D, McGlennon TW, Fried M. Five-Year Outcomes: Laparoscopic Greater Curvature Plication for Treatment of Morbid Obesity. Obes Surg 2017;27(11):2818-28. doi:10.1007/s11695-017-2709-3
    1. Sohn YB, Kim SJ, Park SW, Kim S-H, Cho S-Y, Lee SH, Yoo KH, Sung KW, Chung JH, Koo HH, Jin DK. The metabolic syndrome and body composition in childhood cancer survivors. Korean J Pediatr 2011;54(6):253-9. doi:10.3345/kjp.2011.54.6.253
    1. Paniagua L, Lohsoonthorn V, Lertmaharit S, Jiamjarasrangsi W, Williams MA. Comparison of waist circumference, body mass index, percent body fat and other measure of adiposity in identifying cardiovascular disease risks among Thai adults. Obes Res Clin Pract 2008;2(3):215-23. doi:10.1016/j.orcp.2008.05.003
    1. Lee YC, Lee WJ, Lin YC, Liew PL, Lee CK, Lin SC, Lee TS. Obesity and the decision tree: predictors of sustained weight loss after bariatric surgery. Hepatogastroenterology 2009;56(96):1745-9.
    1. Kahramanoğlu Aksoy E, Göktaş Z, Albuz Ö, Akpinar MY, Öztürk D, Buluş H, Uzman M. Effects of sleeve gastrectomy on liver enzymes, non-alcoholic fatty liver disease-related fibrosis and steatosis scores in morbidly obese patients: first year follow-up. J Lab Med 2019;43(2):115-22. doi:10.1515/labmed-2018-0181
    1. Cottam S, Cottam D, Cottam A. Sleeve Gastrectomy Weight Loss and the Preoperative and Postoperative Predictors: a Systematic Review. Obes Surg 2019;29(4):1388-96. doi: 10.1007/s11695-018-03666-7
    1. Courcoulas AP, Yanovski SZ, Bonds D, Eggerman TL, Horlick M, Staten MA, Staten MA. Long-term Outcomes of Bariatric Surgery: A National Institutes of Health Symposium. JAMA Surg 2014;149(12):1323-9. doi:10.1001/jamasurg.2014.2440
    1. Mayo Clinic. Triglycerides: Why do they matter? 2020 [accessed 12th January 2021]. Available from: .
    1. Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39(5):924-32. doi:10.1111/liv.13974

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj